~~<i id='42877B1654'><strike id='42877B1654'><tt id='42877B1654'><pre id='42877B1654'></pre></tt></strike></i>~~

Home» focus» focus

focus

author：entertainment 2025-10-06 10:41:55 Page View：529

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Families look for replacement for GSK asthma drug Flovent
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

focus

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

AdobeLife-sciencecompanieshavechangedtheworldwiththebreakthroughvaccinesandtherapeuticstheycreated—a

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

Families look for replacement for GSK asthma drug Flovent

BostonGlobeAcommonlyprescribedmedicationforchildren’sasthmaisdisappearingfrompharmacists’shelves,for